<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Over the past decade, irinotecan has become one of the first-line chemotherapeutic agents used in the treatment of <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Recently, irinotecan has been administered transarterially in order to perform chemoembolization in the liver </plain></SENT>
<SENT sid="2" pm="."><plain>In the limited number of reports available to date using this approach, serious adverse effects have not yet been reported </plain></SENT>
<SENT sid="3" pm="."><plain>In this paper, we describe the formation of an intercostal artery pseudoaneurysm after transarterial chemoembolization with irinotecan-eluting beads in a patient with spinal <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>